Post-transplant hypertension remains a significant risk factor for graft loss, but whether or not specific blood pressure (BP) medications affect graft outcome is still unknown. We assessed the interaction between BP control and antihypertensive drugs on graft outcome. We retrospectively examined clinic BP data for 1662 renal transplant (RTx) patients, transplanted between 1994 and 2000 at our centre. The analysis examined all patients who received central a-agonists and peripheral a-antagonists, beta-blockers, calcium channel blockers (CCBs), angiotensin-converting enzyme (ACE) inhibition (ACEI), angiotensin receptor blockers (ARBs). BP recordings during treatment were categorized for each agent. Thus, a particular BP could be categorized for multiple medications. A total of 1462 patients (pts) (88%) were Caucasian and 800 pts (46%) received cadaveric RTx. There were 10.676.8 BP measurements for each patient post-RTx. CCBs, alone among the classes of antihypertensive drugs evaluated, reduced the risk for graft loss (RR: 0.736; P ¼ 0.035) in the overall analysis. Interestingly, stratifying levels of BP control unmasked a beneficial effect on graft survival of ACEI/ ARB therapy in individuals with higher levels of systolic (4152 mmHg) and diastolic blood pressure (498 mmHg) treated with ACEI/ARBs compared to individuals treated with CCBs (Po0.01 for each). Thus, stabilizing BP is important post-RTx. CCBs are associated with improved rates of graft survival. Their role in a compromised RTx, however, deserves further study. ACEI/ARBs have clear benefits, improving graft survival in individuals with elevated systolic blood pressure and proteinuria. CCBs are not as efficacious in this setting.
Introduction
Kidney transplantation remains the most effective means of renal replacement therapy. Its success continues to be manifest in ever improving graft survival rates. 1 Yet, with such success, kidney transplant recipients are living longer and experiencing more in the way of medical complications, for example, control of hypertension. Such complications may affect them and the function of their allografts. The impact of these medical complications is now receiving increasing scrutiny from individuals who care for these patients. Appropriate control of hypertension, in particular, may have an important role in terms of graft function and survival as it represents an area of nonimmune injury that should be readily amenable to intervention.
The prevalence of hypertension in the transplant population has risen in the last two decades. It now affects 70-90% of all kidney transplant recipients. 2, 3 The factors precipitating hypertension in these patients include pre-existing essential hypertension, native-kidney-mediated hypertension, rejection episodes, and calcineurin inhibition.
Antihypertensive treatment is one of the best methods for slowing progression of native kidney disease. There is every reason to hypothesize that it should also have beneficial effects in kidney transplantation. Opelz et al 4 noted that the level of blood pressure (BP) was associated with improved graft survival, regardless of rejection episodes, in a large registry analysis. In addition, hypertension validated even at 1-year post-transplant serves as a significant predictor of long-term renal allograft survival, independent of baseline renal allograft function. 5 Moreover, hypertension predicted the risk of acute rejection and higher levels of BP preceded episodes of acute rejection in one study. 6 Thus, hypertension appears to have an important role in graft events and graft outcomes.
Unfortunately, the optimal drug regimen, the extent of control of post-transplant hypertension, and the timing of when to achieve such control, remain subjects of debate and investigation. Recent studies have demonstrated the early post-transplant efficacy of calcium channel blockers (CCBs) in kidney transplant recipients. 3, 7 However, there is a paucity of data examining the effects of other classes of antihypertensive medications in kidney transplant recipients beyond short-term clinical trials. We performed a retrospective analysis of data at our centre to examine the use of antihypertensive medications and the level of control of hypertension. Our goal from this analysis was to assess whether we could define a beneficial antihypertensive regimen and a level of hypertension associated with less graft loss.
Methods

Population
A total of 1741 individuals who underwent kidney transplantation at the University of Wisconsin between 1994 and 2000 were included in the analysis. To be included in the analysis, individuals had to have graft function for at least 6 months following the date of transplant surgery. They had to be maintained on a medical regimen that included an antihypertensive medication at 6 months posttransplantation and they had to continue on that antihypertensive drug for at least 9 continuous months following the initial 6 months of graft function. That antihypertensive drug was termed the primary agent and used for categorizing any medication effects. If a patient was taking two or more antihypertensive drugs at that time, the first drug prescribed as defined in the data set was termed the primary antihypertensive drugs. Finally, they also had to have serial transplant clinic serial BP measurements (X2) no more than 3 months apart during the first year post-transplant and no more than 6 months apart during every post-transplant year thereafter. The initial BP recording for the purpose of this analysis was the 6-month BP, recorded at that clinic visit. BP measurements were made in the transplant clinic with the patient in the sitting position, using a standard sphygmomanometer in the upper extremity. Two readings were taken at each visit and the average of the readings used for the BP measurement. Of this group, 16 individuals did not meet these serial BP recording criteria, leaving 1725 individuals for the final study population.
Standard immunosuppression for these individuals consisted of induction antibody treatment with polyclonal antithymocyte antisera (Thymoglobulin s ) or a monoclonal anti-CD25 antibody (basiliximab or daclizumab). Patients were also treated initially with high-dose corticosteroids, tapered over the first 6 months to 10 mg prednisone daily. Subsequent steroid reduction to 5 mg daily was at the discretion of the primary treating physician.
Patients were also treated with mycophenolate mofetil 1000 mg twice daily and calcineurin inhibition with either cyclosporine A or tacrolimus. There were no significant changes in immunosuppressive regimens during the time frame of the study analysis.
Acute rejection was diagnosed by kidney transplant biopsy. Cellular rejection was treated initially with high-dose corticosteroids and then, if not resolving, with antibody treatment. Vascular or humoral rejection was treated with high-dose steroids, antibody therapy with or without adjunct plasmapheresis. Cyclosporine A (CsA) and tacrolimus (FK506) levels were targeted at 200-300 and 8-12 ng/ml for the first year post-transplant. These are standard target values. Drug levels were monitored initially monthly during the first post-transplant year and then every 3 months thereafter. Targeted drug levels fell to 100-150 ng/ml for CsA by the third to fifth year post-transplant and 4-8 ng/ ml for FK506 by the same time point.
Data collection
Data on kidney transplant recipient variables were prospectively entered into a transplant-specific database and these data were used for analysis. Antihypertensive drugs were classified as central aagonists or peripheral a-antagonists, beta-blockers, calcium channel blockers (CCBs), and angiotensin antagonism with either angiotensin-converting enzyme inhibition (ACEI) or angiotensin receptor blockade (ACEI/ARBs). Notably, ACEI/ARBs were not used extensively in this cohort until after 1997 (o3% of antihypertensive drug use prior to 1997). BP recordings during treatment were categorized for each agent. Thus, a particular BP could be categorized for multiple medications. Changes in systolic BP were used to assess degree of hypertensive control. In addition, mean arterial BP was also used to assess degree of BP control. Mean arterial BP (MABP) was calculated: [(systolic blood pressureÀdiastolic blood pressure)/3] þ diastolic blood pressure. Changes in urinary protein excretion were evaluated by examining dipstick urinalyses, obtained at each clinic visit. Serial spot urine protein to creatinine ratios or timed urinary protein excretions were not performed routinely during the time frame of the data collection period. Hence, an alternative criterion was developed to assess change in urinary protein excretion. Any change from a baseline of 3 þ or 4 þ protein excretion to r 2 þ dipstick protein on urinalysis was deemed a reduction in urinary protein excretion.
Statistical analyses
Univariate analyses for each class of medications as a whole and then repeated, stratifying the patient cohort based on tertile of systolic or diastolic BP. The univariate analyses were performed with a log-rank test. Events that were examined included biopsy-proven rejection, kidney graft failure, reduction in urinary protein excretion, and patient survival.
The effect of class of antihypertensive drug and change in systolic, diastolic and MABP were examined using a Cox proportional hazards model. The model included: donor age, patient age, patient gender, history of acute rejection, diabetes (type I or type II), type of transplant (deceased or living donor), tobacco use, presence or absence of hyperlipidaemia at 6 months post-transplant (fasting total serum cholesterol 4200 mg/dl), and BP monotherapy at 6 months post-transplant as variables. The univariate analyses were performed using the SAS statistical software (SAS Institute, Inc., Cary, NC, USA). Data are reported as mean7standard deviation. A P-value r 0.05 was considered significant.
Results
Population and antihypertensive drugs
In total, 800 patients (45. 7%) received deceased donor kidney transplants ( Table 1) . The majority of patients were Caucasian and had undergone primary transplantation. More than half were male. Their average age at time of kidney transplantation was slightly greater than 43 years of age. Average follow-up was 26.7 months (range 18-84 months).
The largest group of patients in the cohort received CCBs (n ¼ 673) as their primary antihypertensive drugs (Table 1 ). An overwhelming majority of these drugs were dihydropyridine CCBs (91%). Nifedipine and amlodipine accounted for 88% of all CCBs. Combination therapy was used in 40% of the study population at 6 months post-transplant (n ¼ 598) and 43.3% of the study population at 12 months post-transplant (n ¼ 748). The most common combination regimens at both time points were CCB plus beta-blocker and CCB plus a peripheral a-antagonist.
There were 10.676.8 BP measurements for each patient during the study time period. We stratified the patient population into tertiles of systolic and diastolic BP, based on the mean serial BP values. A systolic BP 4152 mmHg defined the cohort with the most poorly controlled hypertension. A diastolic BP 498 mmHg defined the diastolic threshold for the cohort with the most poorly controlled hypertension poorest as well. The best level of control for hypertension was stratified by a systolic BP (SBP) o124 mmHg and a diastolic BP (DBP) o76 mmHg.
Rejection and graft LOSS
Rejection and BP Using the definition of primary antihypertensive drugs, we then examined for any effect of BP or class of agent altering the risk for acute rejection. We did not identify a significant association between elevated BP and biopsy-proven acute rejection, although there was a trend suggesting that increased systolic BP increased rejection risk (5 mmHg increase in systolic BP relative risk for rejection (RR): 1.1; P ¼ 0.09; 95% confidence interval (CI) 0.94-1.14).
Rejection and medications
There was no significant class effect of any of the antihypertensive drugs, either increasing or decreasing the risk for biopsy-proven acute rejection.
Graft loss and BP Each 5 mmHg increase in SBP was also associated with an increased risk for graft loss (RR: 1.12; P ¼ 0.016; 95% CI 1.03-1.21). Notably, each 5 mmHg increase in SBP was also associated with reduced patient survival (RR: 1.1; Po0.048; 95% CI 1.06-1.14). Each 5 mmHg increase in mean arterial pressure (MAP) 485 conferred an increased risk for graft loss (RR: 1.06; P ¼ 0.042; 95% CI: 1.00-1.16). There was no discrete MABP value that demonstrated a threshold effect with regards to graft loss. Notably, each 5 mmHg incremental increase in MAP485 also was associated with reduced patient survival (RR: 1.16; P ¼ 0.039; 95% CI: 1.01-1.34). 
Graft loss and medications
CCBs were associated with a reduced risk for graft loss in the overall population (RR: 0.736; P ¼ 0.0355; 95% confidence intervals CI: 0.553-0.979) ( Table 2 ). There were no significant differences when comparing CsA vs FK506-treated patients. Notably, there also was no significant difference when we analysed the kidney transplant alone cohort. We performed this analysis to remove any potential confounding effect mediated by the inclusion of the simultaneous pancreas-kidney transplant recipients in the study cohort.
Interaction between antihypertensive drugs and the quality of hypertension control
We developed a proportional hazards model to further assess the possible interactive effect of level of control of hypertension and antihypertensive drugs on graft loss. Variables in the model included donor age, patient age, patient gender, history of acute rejection, diabetes (type I or type II), type of transplant (deceased or living donor), tobacco use, presence or absence of hyperlipidemia at 6 months post-transplant (fasting total serum cholesterol 4200 mg/dl), and BP monotherapy at 6 months post-transplant as variables. SBP, DBP, and MABP were treated as time-varying covariates. A significant association between higher levels of SBP (RR: 1.05; 95% CI 1.03-1.09; P ¼ 0.026), DBP (RR: 1.03; 95% CI 1.01-1.09; P ¼ 0.04) and MABP (RR: 1.02; 95% CI 1.00-1.06; P ¼ 0.039) remained present when examined in the Cox regression model ( Table 3 ). The beneficial effect of CCBs remained significant in the model (RR: 0.81; 95% CI 0.68-0.96). ACEI/ARBs were associated with a trend towards a decreased risk for graft loss (RR: 0.802; 95% CI 0.73-1.05; NS, P ¼ 0.1).
CCBs vs ACEI/ARBs
To assess the potential benefits or detriments of these medications in the post-transplant setting, we stratified the analysis by BP tertiles and then compared rates of graft survival between those with CCBs as primary agents vs those with ACEI/ARBs as primary agents. This analysis unmasked a salutary effect on graft survival specific to ACEI/ARB use in the cohorts with the highest SBP (Po0.01) (Figure 1 ). The same relationship was evident with ACEI/ARB associated with improvements in graft survival in the cohort with the highest level of diastolic hypertension (Po0.01) (Figure 2) . None of the other medications demonstrated a significant effect in decreasing the risk for graft loss.
Effect of antihypertensive drug on urinary protein excretion
In total, 247 individuals in the study population experienced a reduction in urinary protein excretion from 3 þ to 4 þ on urinalysis to p2 þ on follow-up urinalysis. ACEI/ARBs were the only class of antihypertensive drugs that were associated with a decrease in urinary protein excretion (RR:0.68; 95% CI 0.413-0.932; P ¼ 0.041). Notably, the effect of reducing proteinuria through ACEI/ARB use appeared to most significant in the cohort of individuals with the highest levels of SBP as 168 individuals with urinalysis values were in this patient category.
Given the potential for confounding results using only urinalysis results and the fact that until recently, our transplant clinic did not routinely perform spot urine protein/urine creatinine ratios, we further examined whether ACEI/ARBs were effective in reducing urinary protein excretion by assessing all patients who received this class of medications (as either monotherapy or in combination therapy) and whether or not such patients experienced a decline in urinary protein excretion X500 mg/day. This degree of reduction in urinary protein excretion has been associated with improved long-term outcomes in native kidney disease states. 8 ACEI/ARBs (n ¼ 69) were associated with a significant improvement in urinary protein excretion compared to monotherapy or combination therapy with other agents (n ¼ 52) (P ¼ 0.0026).
Discussion
The aim of this study was to assess the effects of different classes of antihypertensive agents on kidney graft survival in our population. Increased SBP, DBP, and MAP were associated with decreased graft survival, similar to other reports. We noted two other important treatment effects. A discrete CCB treatment effect was apparent, associated with increased graft survival. Furthermore, we found that ACEI/ARBs were very effective in controlling proteinuria. Moreover, in the subset of patients with the highest levels of hypertension, ACEI/ARBs had the greatest benefit of all antihypertensive medications examined in terms of improving graft survival.
Increased SBP was associated with decreased graft survival in this cohort of transplant recipients. This is one of several transplant-specific studies to note this relationship and it is consistent with the effect of hypertension in nearly every other form of kidney disease. Opelz et al, 4 in a large registry analysis, demonstrated that increased levels of SBP and DBP post-transplant were associated with a graded increase in graft failure, even when data were death-censored. Mange et al 5 demonstrated similar findings in a single-centre cohort analysis. SBP, DBP, and MAP post-transplant were significant predictors of long-term renal allograft survival. The association between BP and allograft survival appeared linear without a threshold value below which improvements in allograft outcomes no longer occurred. Our findings were congruent with these seminal studies.
Surprisingly, CCBs demonstrated significant benefits in terms of graft survival, potentially, in part, due to their ability to control blood pressure. CCBs counteract many of the detrimental haemodynamic consequences of calcineurin inhibitors 9, 10 and, it is this effect that may account for their demonstrated efficacy increasing GFR in transplant recipients. 11 Furthermore, CCBs tend to have a greater antihypertensive effect in salt-sensitive hypertension, especially when salt intake is ad libitum. This also could explain their greater efficacy in reducing BP in this kidney transplant cohort. The ACEI/ARB effect on graft survival in the subset of individuals with the greatest degree of hypertension demonstrates the beneficial effect of these drugs, especially when they are used in individuals with proteinuria and/or chronic kidney disease, scenarios replicated in the patient population in this study. It should be noted, however, that ACEI/ARB use was not independently associated with improvement in allograft survival in the overall analysis, despite our previous report that ACEI/ARB use does slow the rate of decline in kidney transplant recipients. 12 This may represent a lack of utilization of these drugs early in the time frame of this study.
ACEI/ARB use decreased proteinuria in this study. ACEI/ARB use is the standard of care for proteinuric patients with native kidney-mediated chronic kidney disease. Yet, ACEI/ARB use in kidney transplant patients has been controversial, so much so, that a recent paper focused solely on the safety of these agents in this population. 13 It is notable that improved control of proteinuria was a common event in the cohort of patients with the greatest degree of hypertension. Based on our analysis, prospective trials examining ACE/ARB use in this set of patients are warranted to establish firmly whether they are efficacious in the transplant setting. Such studies should also examine ACEI/ ARB plus CCB therapy. The inherent shortcomings of this 'clinical practice' study and the small number of patients who meet those therapeutic criteria obviate an answer to that question with this analysis alone.
Our study has limitations. This is a retrospective, single-centre analysis with an artificially developed mechanism to assess the impact of exposure to various antihypertensive medications. Moreover, these data are, for the most part, probably only applicable to the Caucasian population, given the demographic breakdown of the population examined in this analysis. This study construct was not designed to determine the impact of combination treatment regimens, changing treatment regimens, nor the effects of other antihypertensive drugs not categorized into these groups. Some patients may have been restarted on pretransplant medications during the post-transplant time frame simply by virtue of convenience. This readily could have introduced a source of bias into the analysis. Unfortunately, our data set was prospectively collected from the time of transplant so many pretransplant variables are missing, including complete pretransplant medication profiles. Thus, corroborating whether such choices guided therapy is difficult.
Despite these caveats, we believe that the data from this study are still noteworthy. We have delineated associations between specific antihypertensive medications and outcomes. Such findings highlight aspects of clinical practice and raise questions about the applicability of hypertension management guidelines across all populations of chronic kidney disease patients. Some authors have already gone so far as to proclaim (tentatively) targets for hypertension control in kidney transplant patients. 14 Others have hypothesized on what medications might be best to use. 15 Yet, we would contend that they have done so without a large body of data to support these conclusions. The data herein provide these parameters and almost mandate that they be examined in adequately powered prospective studies.
